• OPEN AN ACCOUNT
Indian Indices
Sensex
82,344.68 487.20
( 0.60%)
Global Indices
Nasdaq
49,020.90 -412.51
(-0.83%)
Dow Jones
6,999.25 28.02
(0.40%)
Hang Seng
53,273.44 -60.10
(-0.11%)
Nikkei 225
10,215.77 66.92
(0.66%)
Forex
USD-INR
91.65 0.01
(0.01%)
EUR-INR
108.74 0.34
(0.32%)
GBP-INR
125.29 0.27
(0.21%)
JPY-INR
0.59 0.01
(1.05%)

EQUITY - MARKET SCREENER

Glaxosmithkline Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Multinational
BSE Code
ISIN Demat
Book Value()
500660
INE159A01016
100.5174369
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
GLAXO
41.87
39625.77
EPS(TTM)
Face Value()
Div & Yield %
55.87
10
2.31
 

simplex papers ltd
Ram Ratna Wires receives approval under RIPS-2024 for its Bhiwadi plant
Nov 07,2025

Ram Ratna Wires announced that its Bhiwadi plant has been approved under the Rajasthan Investment Promotion Scheme (RIPS-2024). This approval entitles the company to receive Turnover Linked Incentive of 1.32% (in % of EFCI), along with Electricity Duty Exemption for 7 years and 25% Stamp Duty Reimbursement.

The Bhiwadi facility is expected to become a major growth driver for the company, strengthening Ram Ratna Wires' manufacturing capabilities and enabling us to serve high-demand markets more efficiently. With an approved Eligible Fixed Capital Investment (EFCI) of Rs 186.77 crore under RIPS-2024, the plant will benefit from fiscal incentives that enhance operational efficiency and cost competitiveness, contributing to profitability and reinforcing our leadership position in the industry.